Complement C1s subcomponent (C1s)

Complement C1s subcomponent is a vital serine protease within the C1 complex, which serves as the initiator of the classical complement pathway in the innate immune system. It is activated by the C1r subcomponent after the C1 complex binds to antigen-antibody complexes (IgG or IgM) on the surface of pathogens or host cells. Once activated, C1s catalyzes the proteolysis of complement components C4 and C2 to generate the C3 convertase, a critical step that propagates the complement cascade leading to opsonization, inflammation, and cell lysis. In pathological conditions such as Cold Agglutinin Disease (CAD), C1s is inappropriately activated by autoantibodies bound to red blood cells, resulting in chronic hemolysis and anemia. Therapeutic targeting of C1s, primarily through the FDA-approved monoclonal antibody sutimlimab, allows for the selective inhibition of the classical pathway while preserving the alternative and lectin pathways necessary for host defense. Beyond CAD, C1s is implicated in various autoimmune disorders like systemic lupus erythematosus and rare genetic conditions such as periodontal Ehlers-Danlos syndrome, making it a significant target for immunomodulatory therapies.

Other names

C1 esteraseComplement component 1 subcomponent sC1ShC1SComplement C1s subcomponent light chainComplement C1s subcomponent heavy chain

Sutimlimab is a humanized monoclonal antibody that specifically binds to the C1s subcomponent of the C1 complex, inhibiting its serine protease activity. This blockade prevents the cleavage of complement components C4 and C2, thereby halting the formation of the classical pathway C3 convertase (C4bC2a) and preventing downstream hemolysis and inflammation.